Combination therapy with p53–MDM2 binding inhibitors for malignancies

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

(2015) Asfar S. Azmi et al.   Oncotarget

Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process

(2012) M. Rahmani et al.   BLOOD

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

(2012) G. Zauli et al.   HAEMATOLOGICA

HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas

(2012) Angela M Sosin et al.   Journal of Hematology & Oncology

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

(2011) R. J. Jones et al.   BLOOD

p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells

(2011) L F Peterson et al.   LEUKEMIA

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

(2010) J. Long et al.   BLOOD

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment

(2010) Sergey V Tokalov et al.   BMC CANCER

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma

(2010) Linhua Jin et al.   CANCER LETTERS

Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers

(2010) Tatsuhiro Ohgami et al.   CANCER SCIENCE

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

(2010) C F Cheok et al.   CELL DEATH AND DIFFERENTIATION

Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy

(2010) A.S. Azmi et al.   CURRENT CANCER DRUG TARGETS

Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation

(2010) Hong-rong Fei et al.   CYTOTECHNOLOGY

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function

(2010) Asfar S. Azmi et al.   EUROPEAN JOURNAL OF CANCER

Treatment of Ovarian Cancer Cells with Nutlin-3 and Resveratrol Combination Leads to Apoptosis via Caspase Activation

(2010) Palanisamy Marimuthu et al.   JOURNAL OF MEDICINAL FOOD

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses

(2010) M. N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations

(2010) A. S. Azmi et al.   MOLECULAR CANCER THERAPEUTICS

MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53

(2009) J A Canner et al.   BRITISH JOURNAL OF CANCER

Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity

(2009) Rebecca Voltan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacological activation of the p53 pathway in haematological malignancies

(2009) M. N Saha et al.   JOURNAL OF CLINICAL PATHOLOGY

An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals

(2009) Ramzi M Mohammad et al.   Molecular Cancer

High level MycN expression in non-MYCN amplified neuroblastoma is induced by the combination treatment nutlin-3 and doxorubicin and enhances chemosensitivity

(2009) Peirce   ONCOLOGY REPORTS

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP

(2008) J. Lu et al.   CANCER RESEARCH

Targeting the ubiquitin-proteasome system for cancer therapy

(2008) Yili Yang et al.   CANCER SCIENCE

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

p53: A Guide to Apoptosis

(2008) Erik Meulmeester et al.   CURRENT CANCER DRUG TARGETS

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

(2008) K S M Smalley et al.   ONCOGENE

Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis

(2008) Z N Demidenko et al.   ONCOGENE

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA